When Will Life Return to Normal? In 7 Years at Today's Vaccine Rates
(Bloomberg) -- When will the pandemic end? It's the question hanging over just about everything since Covid-19 took over the world last year. The answer can be measured in vaccinations.
Bloomberg has built the biggest database of Covid-19 shots given around the world, with more than 119 million doses administered worldwide. U.S. science officials such as Anthony Fauci have suggested it will take 70% to 85% coverage of the population for things to return to normal. Bloomberg's Vaccine Tracker shows that some countries are making far more rapid progress than others, using 75% coverage with a two-dose vaccine as a target.
Israel, the country with the highest vaccination rate in the world, is headed for 75% coverage in just two months. The U.S. will get there just in time to ring in the 2022 New Year (though North Dakota could get there six months sooner than Texas). With vaccinations happening more rapidly in richer Western countries than the rest of the globe, it will take the world as a whole seven years at the current pace.
Bloomberg's calculator provides a snapshot in time, designed to put today's vaccination rates into perspective. It uses the most recent rolling average of vaccinations, which means that as vaccination numbers pick up, the time needed to hit the 75% threshold will fall.
Brace Yourself: Long-Haul Travel May Not Get Going Until 2023
The calculations will be volatile, especially in the early days of the rollout, and the numbers can be distorted by temporary disruptions.
For example, New York's target date was briefly pushed out to 17 months this week after a winter blizzard prevented some from getting vaccinated (it's now back down to 13 months). Likewise, Canada's vaccination rate dropped by half in recent weeks following reports of delayed vaccine shipments. Based on Canada's latest rate of inoculations it would take more than 10 years to reach 75% coverage. That might serve as a wake-up call to Canadian politicians and health officials, but it doesn't mean the country is doomed to a decade of social distancing. Canada has contracts to buy more vaccine doses per person than any other country, and its vaccination rates are expected to climb.
The pace is likely to accelerate further as more vaccines become available. Some of the world's biggest vaccine-manufacturing hubs in India and Mexico are only just getting started. More than 8.5 billion doses of vaccine have been contracted by countries through more than 100 agreements tracked by Bloomberg. Only a third of countries have even begun their vaccination campaigns.
Getting to Herd Immunity
Vaccinations protect against Covid-19 within a few weeks of getting the shots. But if just a few people in a community get vaccinated, the virus can continue to spread unchecked. As more people get the vaccine, groups of people start to build a collective defense against the virus so that isolated sparks of infection burn out instead of spreading into an outbreak. The concept is known as herd immunity.
In the scientific community, there are conflicting definitions for when herd immunity is achieved. Is it when enough people are protected that it begins to have a measurable effect on the speed of transmission? That could begin well before 75% of people are fully vaccinated. Others define it as the point when outbreaks can no longer be sustained. For example, even if there's a cluster of measles cases in an unvaccinated community, herd immunity prevents it from rippling across a country.
How We Run the Numbers
The vaccines available today require two doses for full vaccination. Our calculations for coverage are based on two doses per person in the population but don't distinguish between first doses or second doses administered. Those breakdowns can distort daily vaccination rates and aren't available in more than 20% of the countries we're tracking.
A new vaccine by Johnson & Johnson recently showed positive results using a single dose in a large clinical trial. If approved, we'll adjust the number of doses required proportionate to its market share in each country.
The vaccines haven't been authorized for use in children — those studies are currently underway. Our calculator, like the virus, includes children in the population needed to be protected.
One metric Bloomberg's calculator doesn't account for is any level of natural immunity that might result from recovering from Covid-19. It's possible that hard-hit places might require a lower level of vaccination to prevent widespread transmission. While there's evidence that people who recover from illness do retain some level of natural defenses, it's unclear how much protection is offered or how long it might last. The vaccine is still recommended for people who have recovered from illness.
The calculator is the latest feature from Bloomberg's Covid-19 Tracker. The projections are updated daily and are based on the average daily vaccinations in data gathered from 67 countries and the U.S. states and territories. Countries may be excluded when they are in the earliest stages of vaccinations or if they provide infrequent updates on their vaccination numbers.
More than 119 million shots have been given. See the latest numbers on Bloomberg's Covid-19 Vaccine Tracker
©2021 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.